...
首页> 外文期刊>MicrobiologyOpen >Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa
【24h】

Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa

机译:美洛昔康抑制铜绿假单胞菌的生物膜形成并增强抗菌剂功效

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Microbial biofilms are communities of surface‐adhered cells enclosed in a matrix of extracellular polymeric substances. Bacterial cells in biofilm are 10~1,000‐fold more resistant to antimicrobials than the planktonic cells. Burgeoning antibiotic resistance in Pseudomonas aeruginosa biofilm has necessitated the development of antimicrobial agents. Here, we have investigated the antibiofilm effect of meloxicam against P.?aeruginosa PAO1 and its potential mechanisms. Further, we have explored whether meloxicam could enhance the susceptibility of bacterial biofilms to treatment with conventional antimicrobials. Here, we found that meloxicam could significantly inhibit PAO1 biofilm formation in a dose‐dependent manner at the concentration without influence on planktonic cell growth. Meloxicam could also significantly inhibit the motilities, production of extracellular matrix, and expression of quorum sensing‐related genes and virulence factors of PAO1. Furthermore, synergistic interaction was observed when meloxicam combined with tetracycline, gentamicin, tobramycin, ciprofloxacin, ceftriaxone, ofloxacin, norfloxacin, ceftazidime, and DNase at subminimal inhibitory concentrations against PAO1 bioiflm. Collectively, our study lays the foundation for further investigation of repurposing meloxicam as a topical antibiofilm agent to treat P.?aeruginosa biofilm‐related infections.
机译:微生物生物膜是封闭在细胞外聚合物基质中的表面粘附细胞群落。生物膜中的细菌细胞对细菌的抗性比浮游细胞高10到1,000倍。在铜绿假单胞菌生物膜中增强抗生素抗性已经需要开发抗微生物剂。在这里,我们研究了美洛昔康对铜绿假单胞菌PAO1的抗生物膜作用及其潜在机制。此外,我们已经探索了美洛昔康是否可以增强细菌生物膜对常规抗菌药物治疗的敏感性。在这里,我们发现美洛昔康可以在不影响浮游细胞生长的浓度下以剂量依赖的方式显着抑制PAO1生物膜的形成。美洛昔康还可能显着抑制PAO1的功能,胞外基质的产生以及群体感应相关基因和毒力因子的表达。此外,当美洛昔康与四环素,庆大霉素,妥布霉素,环丙沙星,头孢曲松,氧氟沙星,诺氟沙星,头孢他啶和DNase联合使用时,对PAO1生物膜的抑制浓度均低于最低限度。总的来说,我们的研究为进一步研究重新使用美洛昔康作为局部抗生物膜药物治疗绿脓杆菌与生物膜相关的感染奠定了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号